SOURCE: Active Biotech

November 08, 2007 02:41 ET

Active Biotech Interim Report Jan-Sep 2007

LUND, SWEDEN--(Marketwire - November 8, 2007) -


* Laquinimod
- recruitment to the Phase III program ongoing
- results from the extension study strengthen Phase II data
- new positive preclinical data presented
- new indications under evaluation

* ANYARA
- Phase II/III trials proceeding according to plan

* TASQ
- Phase II studies initiated

* 57-57
- Phase Ib study proceeding according to plan

* RhuDex®
- Phase IIb study proceeding according to plan
- US patent approved

* I-3D
- positive preclinical data presented

* Net sales SEK 8.7 M (64.1)

* Operating loss SEK 147.8 M (loss: 73.7)

* Loss after tax SEK 152.0 M (loss 82.9)

* Loss per share for the period amounted to SEK 3.30 (loss 2.09)


For further information, please contact:
Sven Andréasson
President and CEO
Tel: +46 (0)46-19 20 49

Cecilia Hofvander
Manager Corporate Communication
Tel: +46 (0)46-19 11 22

Active Biotech AB (Corp. Reg. No. 556223-9227)
PO Box 724
SE-220 07 Lund
Sweden
Tel. +46 (0)46-19 20 00
Fax +46 (0)46-19 20 50
This report is also available at www.activebiotech.com

Active Biotech Interim Report Jan-Sep 2007: http://hugin.info/1002/R/1166898/228663.pdf


Copyright © Hugin ASA 2007. All rights reserved.

Contact Information